Select acquires remainder of subsidiaries

By Melissa Trudinger
Tuesday, 30 November, 2004

Select Vaccines (ASX: SLT) will acquire the remaining 35 per cent of its two subsidiaries Picoral and Hepgenics from the Burnet Institute.

The institute will be issued 4 million new shares plus 2 million options in Select Vaccines in return for its equity.

Ongoing R&D programs being conducted by the Burnet Institute for the two companies will continue to be funded through December 2005.

Related News

New drug to prevent migraine claimed to work straight away

People taking atogepant showed improvement on assessments of how much migraine impaired their...

Your stool can reveal your risk of cardiovascular disease

Certain faecal proteins have been linked to deadly cardiovascular conditions. A connection...

Targeting the stress system reduces Parkinson's tremors

The commonly used Parkinson's drug levodopa usually helps with tremors, but it tends to be...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd